Pfizer is the latest biopharma giant over the past couple of years to launch a collaboration focused on molecular glues, reflecting a growing interest in the space. “It has become clear lately that ...
The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.
Some results have been hidden because they may be inaccessible to you